AbbVie

WHCD Shooting, DOJ Ends Powell Probe, Musk Vs. Altman and More in Morning Squawk

AAN 2026: Tavapadon Post-Hoc Analysis Strengthens Its D1/D5 Agonist Pitch

Asian Marco Initial Thoughts: US/Iran Stand-Off the Main Focus; Oil Price Rising. Warsh Nomination for Fed Chair to Be Voted on Wednesday, Central Banks Rate Decisions in Focus This Week.

AbbVie Tries a New Approach in 340B Programme Battle

Pharma 5.0, Sustainability & Security: PHARMAP 2026 Brings Pharma’s Future Into Focus

Merck Backs Off Revolution After Failing To Agree on Price: WSJ

AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules

STAT+: Pharmalittle: We’re Reading About FDA Seeking More Data on a Lilly Obesity Pill, a Pharma 340B Win, and More

4 Spaces Primed for the Next Wave of Gene Therapies

Biotech in 2025: A Retrospective 

AbbVie Sinks Talons Into KRAS with Right to Buy Kestrel for up to $1.45B

AI, Gene Therapies Drive Market Trends in Eye Care

FDA Sets Feb. 1 Launch Date for PreCheck Pilot To Strengthen Domestic Supply Chain

In a First, a Drugmaker’s Lawsuit Challenges HRSA’s 340B Patient Definition

FDA Declines to Approve AbbVie's Botox Follow-Up

Brepocitinib Approval May Be ‘Highlight of the Derm-Rheum World’

The Rise of Trispecific Antibodies: Biopharma’s Next Big Bet After Bispecifics

IQMP Funds Five Quantum Algorithm Projects With New Awards

Senju Launches First-in-Class Dry Eye Disease Drug in Japan

AbbVie Submits FDA NDA for Upadacitinib (RINVOQ) to Treat Severe Alopecia Areata

Analysis Finds Efficiencies, Savings of Using a Single Bispecific for DLBCL and FL

Amgen Adds AML Candidate in Deal for U.K.-based Dark Blue: Deals Report

Taking a Look at the Toxicity Trade-Offs of EPCORE FL-1

Hepatitis Vaccine Uptake Declining, Liver Disease Could Increase

AbbVie Inc (ABBV) Q1 2026 Earnings Call Transcript

AAN 2026: Head-to-Head Trial Shows Superiority of Qulipta for Migraine Prevention

Siemens, Diageo, Oxbo and Others Open US Facilities in April

UCB to Acquire Candid Therapeutics for $2 B, Adding T‑Cell Engager Platform to Immunology Portfolio

AbbVie Says Immunology Blockbusters Will Be 'Main Drivers' Of Growth Post-Humira

Novartis Antimalarial Clears Key WHO Review to Get the Combo Drug to Babies

Pharmaceutical Executive Daily: FDA Issues CRL to AbbVie

Trump’s New Drug Advertising Proposals Fall Short on Public Health and the Constitution

Toward Equitable Access to Cell and Gene Therapies: Rethinking Co-Payments

AbbVie’s New Immunology Standard-Bearer Skyrizi Kneels to UCB’s Bimzelx in Psoriatic Arthritis

FDA Revises Recommendation on First Full Epcoritamab Dose in R/R DLBCL to Allow Outpatient Monitoring

Medicare Can Save $4 Billion On Four Cancer Drugs – Can You Guess Which Ones?

Foslevadopa/Foscarbidopa Saved Resources in Parkinson’s

Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal

AbbVie (ABBV) Maintains Dividend Strength as Core Drugs Drive Cash Flow

The Top 10 PharmTech Videos of 2025

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat

Hikma V. Amarin: The Amici Speak – Part II

Inside NImmune’s Phase 3 Push in Ulcerative Colitis

Proteasomes: A Novel Approach to Target the Immune System

FDA to Meet Novo Nordisk on Troubled Site; AbbVie Buys Drug-Device Factory

CMS's Medicare Price Negotiations Start Round Three

Sarepta, Amylyx and Neumora Look Ahead to Key Catalysts as Q1 Earnings Roll In

AI Giant Anthropic Leans Into Life Sciences With $400M Coefficient Bio Catch

Neomorph Raises $100M for Molecular Glues; Spyre's Ulcerative Colitis Data

Tenpoint Wins FDA Nod for Combination Presbyopia Eye Drop

AbbVie to Fund Kestrel Therapeutics with up to $1.45B in Strategic Agreement, Includes Option to Acquire

AbbVie Secures Option to Acquire Kestrel Therapeutics for Up to $1.45B

AbbVie Acquires Drug-Device Factory

Disco Pharmaceuticals Secures €36M Seed Funding